Brookfield Corporation Looks More Like Berkshire Hathaway Every Year. Is It Time to Buy?

Brookfield Corporation is presented as trading well below intrinsic value, with estimated value at $68 per share versus a recent $50 price and a projected $140 by 2030. The article highlights 22% annualized distributable earnings growth from $2.7 billion in 2021 to $5.3 billion last year, plus a target of 25% EPS CAGR over the next five years. AI infrastructure investment, insurance/wealth solutions expansion, and a real estate recovery are cited as key growth drivers.

Analysis

The market is still pricing BN like a financially engineered holding company, not a capital allocator with an emerging liability-duration advantage. The second-order implication of scaling insurance is not just access to float; it is access to a sticky, lower-beta source of long-duration capital that can be recycled into illiquid assets when public markets are dislocated. That makes BN a beneficiary of higher-for-longer rates only if asset yields reprice faster than liability costs; otherwise the spread on new annuity issuance can compress before the investment side fully re-marks upward.

The AI-infrastructure angle is the most important incremental catalyst, but it is also the easiest place for consensus to overearn. The real winners inside the BN complex are the adjacent cash-generators with scarce permitting, grid access, power, and industrial land exposure; the losers are capital-intensive digital infrastructure developers that need external financing and may face rising construction costs, slower lease-up, or power bottlenecks. If AI capex stalls even modestly, the incremental earnings path likely shifts from a 2026-2028 story to a later-cycle 2028-2030 one.

The valuation gap can remain open for longer than bulls expect because the equity still trades like a sum-of-parts discount story, while the market is demanding proof that insurance, private markets, and infrastructure can compound together through one cycle. The key contrarian miss is that BN’s upside may be less about intrinsic value realization and more about multiple expansion from de-risking the earnings stream; if distributable earnings growth stays above 15% and the insurance platform keeps scaling, the stock can rerate without needing heroic AI assumptions. Conversely, any underwriting slip, mark-down in real estate, or capital allocation mistake would pressure the narrative quickly, because the market is effectively paying for flawless execution across several moving parts.

Key Decisions for Investors

• Long BN on a 6-12 month horizon via common stock; use weakness toward post-earnings drawdowns as entry. Risk/reward favors a 20-30% upside rerate if the market starts underwriting the insurance float as durable capital rather than balance-sheet leverage.
• Pair trade: long BN / short BRK.B for a 9-18 month relative-value thesis. BN has more embedded AI and private-markets option value; downside is higher execution risk, so size smaller than a plain long.
• Overweight BAM versus BN if you want cleaner exposure to asset-gathering and AI infrastructure optionality with less balance-sheet complexity. BN is the better upside vehicle, but BAM should outperform if investors keep discounting insurer-specific risk.
• Sell downside via short-dated cash-secured puts on BN around earnings or major AI-catalyst headlines. The implied-volatility premium is attractive if you are willing to own the stock below current levels, with a favorable theta capture over 1-3 months.
• Avoid chasing the broader AI infrastructure basket blindly; prefer BN-adjacent names with power, grid, or land scarcity. If AI capex rolls over, the pure developers should derate faster than BN’s diversified capital base.